Germinated Barley Significantly Reduces Clinical Symptoms of Ulcerative Colitis
Abstract Title:
Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial.
Abstract Source:
J Gastroenterol. 2002 Nov;37 Suppl 14:67-72. PMID: 12572869
Abstract:
BACKGROUND:
Germinated barley foodstuff (GBF) is a prebiotic foodstuff that
effectively increases luminal butyrate production by stimulating the
growth of protective bacteria. In the first pilot study, GBF has been
shown to reduce both clinical activity and mucosal inflammation in
ulcerative colitis (UC). The aim of this study was to investigate the
efficacy of GBF in the treatment of Ulcerative Colitis in a multicenter open control
trial.
METHODS: Eighteen patients with mildly to moderately active Ulcerative Colitis were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20-30 g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal microflora were also analyzed.
RESULTS: After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum.
CONCLUSIONS: Oral GBF therapy may have the potency to reduce clinical activity of Ulcerative Colitis. We believe that these results support the use of GBF administration as a new adjunct therapy for Ulcerative Colitis.
METHODS: Eighteen patients with mildly to moderately active Ulcerative Colitis were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20-30 g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal microflora were also analyzed.
RESULTS: After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum.
CONCLUSIONS: Oral GBF therapy may have the potency to reduce clinical activity of Ulcerative Colitis. We believe that these results support the use of GBF administration as a new adjunct therapy for Ulcerative Colitis.
Article Published Date : Nov 01, 2002
Study Type : Human Study
Additional Links
http://www.ncbi.nlm.nih.gov/pubmed/?term=barley
http://www.ncbi.nlm.nih.gov/pubmed/?term=barley
